{"id":"https://openalex.org/W3213612151","doi":"https://doi.org/10.1002/psp4.12727","title":"Erdafitinib\u2019s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer","display_name":"Erdafitinib\u2019s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer","publication_year":2021,"publication_date":"2021-11-10","ids":{"openalex":"https://openalex.org/W3213612151","doi":"https://doi.org/10.1002/psp4.12727","mag":"3213612151","pmid":"https://pubmed.ncbi.nlm.nih.gov/34755484","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/9124353"},"language":"en","primary_location":{"id":"doi:10.1002/psp4.12727","doi":"https://doi.org/10.1002/psp4.12727","is_oa":true,"landing_page_url":"https://doi.org/10.1002/psp4.12727","pdf_url":null,"source":{"id":"https://openalex.org/S4210231731","display_name":"CPT Pharmacometrics & Systems Pharmacology","issn_l":"2163-8306","issn":["2163-8306"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319908","host_organization_name":"Nature Portfolio","host_organization_lineage":["https://openalex.org/P4310319908","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Nature Portfolio","Springer Nature"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CPT: Pharmacometrics &amp; Systems Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1002/psp4.12727","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5020177847","display_name":"Anne\u2010Ga\u00eblle Dosne","orcid":"https://orcid.org/0000-0002-6937-0910","observed_orcids":["https://orcid.org/0000-0002-6937-0910","https://orcid.org/0000-0002-6298-8494"]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Anne\u2010Ga\u00eblle Dosne","raw_affiliation_strings":["Janssen Research &amp; Development Beerse Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research &amp; Development Beerse Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075190555","display_name":"Elodie Valade","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Elodie Valade","raw_affiliation_strings":["Janssen Research &amp; Development Beerse Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research &amp; Development Beerse Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038570955","display_name":"Kim Stuyckens","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Kim Stuyckens","raw_affiliation_strings":["Janssen Research &amp; Development Beerse Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research &amp; Development Beerse Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061992932","display_name":"Peter De Porre","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Peter De Porre","raw_affiliation_strings":["Janssen Research &amp; Development Beerse Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research &amp; Development Beerse Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066015282","display_name":"Anjali Narayan Avadhani","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anjali Avadhani","raw_affiliation_strings":["Janssen Research &amp; Development Spring House Pennsylvania USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research &amp; Development Spring House Pennsylvania USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025772844","display_name":"Anne O\u2019Hagan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anne O\u2019Hagan","raw_affiliation_strings":["Janssen Research &amp; Development Spring House Pennsylvania USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research &amp; Development Spring House Pennsylvania USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035903068","display_name":"Lilian Yanqing Li","orcid":"https://orcid.org/0000-0001-7507-3632","observed_orcids":["https://orcid.org/0000-0001-7507-3632"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lilian Y. Li","raw_affiliation_strings":["Janssen Research &amp; Development Spring House Pennsylvania USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research &amp; Development Spring House Pennsylvania USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021683079","display_name":"Dani\u00e8le Ouellet","orcid":"https://orcid.org/0009-0006-2794-1283","observed_orcids":["https://orcid.org/0009-0006-2794-1283"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniele Ouellet","raw_affiliation_strings":["Janssen Research &amp; Development Spring House Pennsylvania USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research &amp; Development Spring House Pennsylvania USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045626924","display_name":"Ruben Faelens","orcid":"https://orcid.org/0000-0002-7234-2443","observed_orcids":["https://orcid.org/0000-0002-7234-2443"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ruben Faelens","raw_affiliation_strings":["SGS Exprimo NV, Mechelen, Belgium"],"raw_orcid":"https://orcid.org/0000-0002-7234-2443","affiliations":[{"raw_affiliation_string":"SGS Exprimo NV, Mechelen, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051353999","display_name":"Quentin Leirens","orcid":"https://orcid.org/0000-0002-1468-1359","observed_orcids":["https://orcid.org/0000-0002-1468-1359"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Quentin Leirens","raw_affiliation_strings":["SGS Exprimo NV, Mechelen, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"SGS Exprimo NV, Mechelen, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021392198","display_name":"Italo Poggesi","orcid":"https://orcid.org/0000-0003-3079-6954","observed_orcids":["https://orcid.org/0000-0003-3079-6954"]},"institutions":[{"id":"https://openalex.org/I4210161821","display_name":"Janssen (Italy)","ror":"https://ror.org/05sdrja69","country_code":"IT","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210161821"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Italo Poggesi","raw_affiliation_strings":["Janssen Research &amp; Development Cologno Monzese Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research &amp; Development Cologno Monzese Italy","institution_ids":["https://openalex.org/I4210161821"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5037777365","display_name":"Juan Jos\u00e9 P\u00e9rez Ruixo","orcid":"https://orcid.org/0000-0001-9890-745X","observed_orcids":["https://orcid.org/0000-0001-9890-745X"]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Juan Jose Perez Ruixo","raw_affiliation_strings":["Janssen Research &amp; Development Beerse Belgium"],"raw_orcid":"https://orcid.org/0000-0001-9890-745X","affiliations":[{"raw_affiliation_string":"Janssen Research &amp; Development Beerse Belgium","institution_ids":["https://openalex.org/I137982388"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5020177847"],"corresponding_institution_ids":["https://openalex.org/I137982388"],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":{"value":3000,"currency":"USD","value_usd":3000},"fwci":2.9644,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":{"value":0.91135548,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"11","issue":"5","first_page":"569","last_page":"580"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.2971000075340271,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.2971000075340271,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10516","display_name":"Parathyroid Disorders and Treatments","score":0.23559999465942383,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.1371999979019165,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/erdafitinib","display_name":"erdafitinib","score":1.0},{"id":"https://openalex.org/keywords/serum-phosphorus","display_name":"serum phosphorus","score":0.9649999737739563},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.6520000100135803},{"id":"https://openalex.org/keywords/population-pk-pd-model","display_name":"population PK/PD model","score":0.7450000047683716},{"id":"https://openalex.org/keywords/fibroblast-growth-factor-receptor","display_name":"fibroblast growth factor receptor","score":0.7089999914169312},{"id":"https://openalex.org/keywords/fgf23","display_name":"fibroblast growth factor 23","score":0.7059999704360962},{"id":"https://openalex.org/keywords/dosing-algorithm","display_name":"dosing algorithm","score":0.6119999885559082},{"id":"https://openalex.org/keywords/dose-titration","display_name":"dose titration","score":0.7440000176429749},{"id":"https://openalex.org/keywords/free-drug-concentration","display_name":"free drug concentration","score":0.6029999852180481},{"id":"https://openalex.org/keywords/cancer-patients","display_name":"cancer patients","score":0.5},{"id":"https://openalex.org/keywords/phosphate-monitoring","display_name":"phosphate monitoring","score":0.5239999890327454},{"id":"https://openalex.org/keywords/covariate-effects","display_name":"covariate effects","score":0.35100001096725464}],"concepts":[{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.8502369523048401},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6653430461883545},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6331931948661804},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6091840863227844},{"id":"https://openalex.org/C2777132085","wikidata":"https://www.wikidata.org/wiki/Q46220103","display_name":"Phosphate","level":2,"score":0.554609477519989},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5339862704277039},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.49561774730682373},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.4921835958957672},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3467438817024231},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2382526993751526},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.14702922105789185},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010710","descriptor_name":"Phosphates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D011810","descriptor_name":"Quinoxalines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1002/psp4.12727","doi":"https://doi.org/10.1002/psp4.12727","is_oa":true,"landing_page_url":"https://doi.org/10.1002/psp4.12727","pdf_url":null,"source":{"id":"https://openalex.org/S4210231731","display_name":"CPT Pharmacometrics & Systems Pharmacology","issn_l":"2163-8306","issn":["2163-8306"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319908","host_organization_name":"Nature Portfolio","host_organization_lineage":["https://openalex.org/P4310319908","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Nature Portfolio","Springer Nature"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CPT: Pharmacometrics &amp; Systems Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:9124353","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9124353","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CPT Pharmacometrics Syst Pharmacol","raw_type":"Text"},{"id":"pmid:34755484","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34755484","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CPT: pharmacometrics & systems pharmacology","raw_type":"Journal Article"},{"id":"pmh:oai:lirias2repo.kuleuven.be:20.500.12942/749954","doi":null,"is_oa":true,"landing_page_url":"https://lirias.kuleuven.be/handle/20.500.12942/749954","pdf_url":null,"source":{"id":"https://openalex.org/S7407055369","display_name":"Lirias","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"CPT-Pharmacometrics & Systems Pharmacology, vol. 11 (5), (569-580)","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:doaj.org/article:d207019ca52a4083a1ee53c5220eb93b","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/d207019ca52a4083a1ee53c5220eb93b","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 5, Pp 569-580 (2022)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1002/psp4.12727","doi":"https://doi.org/10.1002/psp4.12727","is_oa":true,"landing_page_url":"https://doi.org/10.1002/psp4.12727","pdf_url":null,"source":{"id":"https://openalex.org/S4210231731","display_name":"CPT Pharmacometrics & Systems Pharmacology","issn_l":"2163-8306","issn":["2163-8306"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319908","host_organization_name":"Nature Portfolio","host_organization_lineage":["https://openalex.org/P4310319908","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Nature Portfolio","Springer Nature"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CPT: Pharmacometrics &amp; Systems Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":15,"referenced_works":["https://openalex.org/W1776781495","https://openalex.org/W2008176460","https://openalex.org/W2022934702","https://openalex.org/W2023327445","https://openalex.org/W2139046059","https://openalex.org/W2161608625","https://openalex.org/W2169170125","https://openalex.org/W2169675402","https://openalex.org/W2242847513","https://openalex.org/W2533683200","https://openalex.org/W2560839005","https://openalex.org/W2760207881","https://openalex.org/W2946128073","https://openalex.org/W2964014383","https://openalex.org/W2990258277"],"related_works":["https://openalex.org/W2990258277","https://openalex.org/W2760207881","https://openalex.org/W3213940250","https://openalex.org/W2036523295","https://openalex.org/W2012332584","https://openalex.org/W7159106781","https://openalex.org/W4391722368","https://openalex.org/W1905382513","https://openalex.org/W2180948707","https://openalex.org/W4309246758"],"abstract_inverted_index":{"A":[0],"population":[1,16],"pharmacokinetic":[2],"(PK)-pharmacodynamic":[3],"(PD)":[4],"model":[5,18,283],"was":[6,189,206,228],"developed":[7],"using":[8],"data":[9],"from":[10,280],"345":[11],"patients":[12,262],"with":[13,81,86,121,162,251],"cancer.":[14],"The":[15,139,199,278],"PK-PD":[17,102,282],"evaluated":[19],"the":[20,52,109,145,168,235,246,259,264,273,281,289],"effect":[21],"of":[22,95,114,137,156,187,193,234,249,261,275,288],"erdafitinib":[23,115,163,290],"total":[24],"and":[25,39,50,71,132,148],"free":[26,164,169],"plasma":[27],"concentrations":[28,32,142,211,268],"on":[29,127,214,255],"serum":[30,59,75,140,196,209,266],"phosphate":[31,60,76,128,141,160,178,197,210,218,227,267,292],"after":[33,79,144,153,182],"once-daily":[34,118],"oral":[35],"continuous":[36,119,157],"(0.5-12":[37],"mg)":[38],"intermittent":[40],"(10-12":[41],"mg":[42,117,125],"for":[43,68,208],"7":[44],"days":[45,47,136,155,186],"on/7":[46],"off)":[48],"dosing,":[49,120],"investigated":[51,236],"potential":[53],"covariates":[54],"affecting":[55],"erdafitinib-related":[56],"changes":[57,293],"in":[58,74,172,176,230],"levels.":[61],"Phosphate":[62],"is":[63],"used":[64],"as":[65],"a":[66,173,203,285],"biomarker":[67],"erdafitinib's":[69,298],"efficacy":[70],"safety:":[72],"increases":[73],"were":[77,84,105,239],"observed":[78],"dosing":[80,112,188,204,299],"erdafitinib,":[82],"which":[83,296],"associated":[85],"fibroblast":[87,97],"growth":[88,98],"factor":[89,99],"receptor":[90],"target":[91,265],"engagement":[92],"via":[93],"inhibition":[94],"renal":[96],"23-mediated":[100],"signaling.":[101],"model-based":[103],"simulations":[104],"performed":[106],"to":[107,123,224,253],"assess":[108],"approved":[110],"PD-guided":[111],"algorithm":[113],"(8":[116],"up-titration":[122,252],"9":[124],"based":[126],"levels":[129],"[<5.5":[130],"mg/dl]":[131],"tolerability":[133],"at":[134,183,220],"14-21":[135,257],"treatment).":[138],"increased":[143,161],"first":[146],"dose":[147,248],"reached":[149],"near":[150],"maximal":[151,195],"level":[152],"14":[154,185],"treatment.":[158],"Serum":[159],"drug":[165],"concentrations:":[166],"doubling":[167],"concentration":[170],"resulted":[171],"1.8-fold":[174],"increase":[175],"drug-related":[177],"changes.":[179],"Dose":[180],"adjustment":[181],"least":[184],"supported":[190],"by":[191],"achievement":[192],">95%":[194],"concentration.":[198],"peak-to-trough":[200],"fluctuation":[201],"within":[202,263],"interval":[205],"limited":[207],"(5.68-5.65":[212],"mg/dl":[213],"Day":[215],"14),":[216],"supporting":[217],"monitoring":[219],"any":[221],"time":[222],"relative":[223],"dosing.":[225],"Baseline":[226],"higher":[229],"women,":[231],"otherwise,":[232],"none":[233],"covariate-parameter":[237],"relationships":[238],"considered":[240],"clinically":[241],"relevant.":[242],"Simulations":[243],"suggest":[244],"that":[245],"starting":[247],"8-mg":[250],"9-mg":[254],"Days":[256],"maximized":[258],"number":[260,274],"(5.5-7":[269],"mg/dl)":[270],"while":[271],"limiting":[272],"treatment":[276],"interruptions.":[277],"findings":[279],"provided":[284],"detailed":[286],"understanding":[287],"concentration-related":[291],"over":[294],"time,":[295],"supports":[297],"algorithm.":[300]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3}],"updated_date":"2026-11-03T10:50:19.383937","created_date":"2021-11-22T00:00:00"}